Literature DB >> 1848608

Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme.

V R Muzykantov1, E A Puchnina, E N Atochina, H Hiemish, M A Slinkin, F E Meertsuk, S M Danilov.   

Abstract

The biodistribution of radiolabeled monoclonal antibody (Mab) to angiotensin-converting enzyme (ACE) was examined in normal and endotoxin-treated rats. Endotoxin administration at a dose of 4 mg/kg induced mild or middle pulmonary edema. The ACE activity in lung homogenate remained virtually unchanged, while the activity of serum ACE increased 15 hr after endotoxin infusion. In normal rats, anti-ACE Mab accumulates specifically in the lung after i.v. injection. Endotoxin injection induces reduction of specific pulmonary uptake of this antibody. Even in non-edematous endotoxemia, the accumulation of anti-ACE Mab antibody (Mab 9B9) decreased from 19.02 to 11.91% of ID/g of tissue without any change in accumulation of control nonspecific IgG. The antibody distribution in other organs and its blood level were almost the same as in the control. In a case of endotoxemia accompanied by increased microvascular permeability, the lung accumulation of Mab 9B9 was reduced to 9.17% of ID/g of tissue, while the accumulation of nonspecific IgG increased to 1.44% versus 0.89% in the control.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848608

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Targeting and imaging signature caveolar molecules in lungs.

Authors:  Kerri A Massey; Jan E Schnitzer
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

Review 4.  Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems.

Authors:  Patrick M Glassman; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

5.  Reduced expression of angiotensin I-converting enzyme in caveolin-1 knockout mouse lungs.

Authors:  Nikolaos A Maniatis; Irina V Balyasnikova; Roman Metzger; Maricela Castellon; David J Visintine; David E Schwartz; Richard D Minshall; Sergei M Danilov
Journal:  Microvasc Res       Date:  2010-04-27       Impact factor: 3.514

6.  Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin.

Authors:  Vladimir V Shuvaev; Raisa Yu Kiseleva; Evguenia Arguiri; Carlos H Villa; Silvia Muro; Melpo Christofidou-Solomidou; Radu V Stan; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2017-12-29       Impact factor: 9.776

7.  ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance.

Authors:  Samuel H Crayton; Drew R Elias; Ajlan Al Zaki; Zhiliang Cheng; Andrew Tsourkas
Journal:  Biomaterials       Date:  2011-11-17       Impact factor: 12.479

Review 8.  Targeting therapeutics to endothelium: are we there yet?

Authors:  Raisa Yu Kiseleva; Patrick M Glassman; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

Review 9.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

10.  Systemic administration of platelet-activating factor in rat reduces specific pulmonary uptake of circulating monoclonal antibody to angiotensin-converting enzyme.

Authors:  E N Atochina; H H Hiemisch; V R Muzykantov; S M Danilov
Journal:  Lung       Date:  1992       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.